Dexmedetomidine vs. Propofol for Cataract Surgery

This study has been completed.
Sponsor:
Information provided by:
The Cooper Health System
ClinicalTrials.gov Identifier:
NCT00786370
First received: November 5, 2008
Last updated: February 9, 2012
Last verified: November 2008
  Purpose

The use of dexmedetomidine in cataract surgery is still limited and to date only one study has examined anesthetic technique in this patient population. This pilot study will therefore compare the use of dexmedetomidine and propofol in subjects undergoing cataract surgery. The primary endpoint will be based on simple cardiorespiratory measures often associated with complications from sedation as well as assessment of the achieved sedation by the attending anesthesiologist and surgeon.


Condition Intervention Phase
Cataract
Drug: dexmedetomidine
Drug: Propofol
Drug: Dexemedetomidine
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Dexmedetomidine vs. Propofol for Monitored Anesthesia Care During Cataract

Resource links provided by NLM:


Further study details as provided by The Cooper Health System:

Primary Outcome Measures:
  • To compare select cardiorespiratory effects of dexmedetomidine sedation to those of propofol sedation in patients undergoing cataract surgery. [ Time Frame: 1 day ] [ Designated as safety issue: Yes ]

Enrollment: 24
Study Start Date: April 2008
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Propofol Drug: Propofol
continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
Experimental: Dexmedetomidine Drug: dexmedetomidine
Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
Drug: Dexemedetomidine
continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Normal renal function
  2. No chronic use of narcotics
  3. ASA PS1-3
  4. Males or females age 18 or older

Exclusion Criteria:

  1. Liver disease (Child Pugh classification 1-3)
  2. History of chronic use of sedatives, narcotics, alcohol or illicit drugs or allergy to any the study medications
  3. History of 1st and 2nd degree heart block (not paced)
  4. Any patient with EF < 30%
  5. Patients with active seizure history
  6. Pregnant patients (women of child bearing potential will have a preoperative pregnancy test as is standard of practice)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00786370

Locations
United States, New Jersey
Cooper University Hospital
Camden, New Jersey, United States, 08103
Sponsors and Collaborators
The Cooper Health System
Investigators
Principal Investigator: Jeffrey Littman, MD The Cooper Health System
  More Information

No publications provided

Responsible Party: Jeffrey Littman, MD, Cooper University Hospital
ClinicalTrials.gov Identifier: NCT00786370     History of Changes
Other Study ID Numbers: RP 08-045
Study First Received: November 5, 2008
Last Updated: February 9, 2012
Health Authority: United States: Institutional Review Board

Keywords provided by The Cooper Health System:
propofol
dexmedetomidine
cataract
respiratory
blood pressure
Cataract surgery

Additional relevant MeSH terms:
Cataract
Lens Diseases
Eye Diseases
Propofol
Dexmedetomidine
Hypnotics and Sedatives
Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Anesthetics, Intravenous
Anesthetics, General
Anesthetics
Analgesics, Non-Narcotic
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014